Health Care [ 5/12 ] | Health Care Equipment & Supplies [ 28/75 ]
NASDAQ | Common Stock
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.
The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing.
MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 12, 25 | -0.12 Decreased by -9.09% | -0.11 Decreased by -5.91% |
| Aug 6, 25 | -0.12 Decreased by -33.33% | -0.10 Decreased by -20.00% |
| Jun 11, 25 | -0.10 Decreased by -11.11% | -0.13 Increased by +23.08% |
| Mar 11, 25 | -0.10 Decreased by -100.00% | -0.12 Increased by +16.67% |
| Nov 6, 24 | -0.11 Increased by 0.00% | -0.12 Increased by +8.33% |
| Aug 6, 24 | -0.09 Increased by +10.00% | -0.13 Increased by +30.77% |
| May 7, 24 | -0.09 Increased by +18.18% | -0.13 Increased by +30.77% |
| Mar 12, 24 | -0.05 Increased by 0.00% | -0.07 Increased by +28.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 6.83 M Decreased by -16.35% | -12.42 M Decreased by -7.43% | Decreased by -181.81% Decreased by -28.43% |
| Jun 30, 25 | 8.51 M Decreased by -18.43% | -12.36 M Decreased by -31.81% | Decreased by -145.26% Decreased by -61.59% |
| Mar 31, 25 | 10.39 M Decreased by -8.39% | -10.26 M Decreased by -7.72% | Decreased by -98.76% Decreased by -17.59% |
| Dec 31, 24 | 8.69 M Decreased by -44.51% | -10.60 M Decreased by -100.78% | Decreased by -121.90% Decreased by -261.80% |
| Sep 30, 24 | 8.16 M Increased by +2.00% | -11.56 M Decreased by -2.71% | Decreased by -141.56% Decreased by -0.70% |
| Jun 30, 24 | 10.43 M Increased by +15.33% | -9.38 M Increased by +10.82% | Decreased by -89.89% Increased by +22.67% |
| Mar 31, 24 | 11.34 M Increased by +32.25% | -9.53 M Increased by +12.46% | Decreased by -83.99% Increased by +33.81% |
| Dec 31, 23 | 15.66 M Increased by +26.09% | -5.28 M Decreased by -9.74% | Decreased by -33.69% Increased by +12.96% |